[HTML][HTML] Phosphorylated tau and the neurodegenerative foldopathies

KS Kosik, H Shimura - Biochimica et Biophysica Acta (BBA)-Molecular …, 2005 - Elsevier
Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 2005Elsevier
Many studies have implicated phosphorylated tau in the Alzheimer disease process.
However, the cellular fate of phosphorylated tau has only recently been described. Recent
work has shown that tau phosphorylation at substrate sites for the kinases Cdk5 and GSK3-
beta can trigger the binding of tau to the chaperones Hsc70 and Hsp27. The binding of
phosphorylated tau to Hsc70 implied that the complex may be a substrate for the E3 ligase
CHIP and this possibility was experimentally verified. The presence of this system in cells …
Many studies have implicated phosphorylated tau in the Alzheimer disease process. However, the cellular fate of phosphorylated tau has only recently been described. Recent work has shown that tau phosphorylation at substrate sites for the kinases Cdk5 and GSK3-beta can trigger the binding of tau to the chaperones Hsc70 and Hsp27. The binding of phosphorylated tau to Hsc70 implied that the complex may be a substrate for the E3 ligase CHIP and this possibility was experimentally verified. The presence of this system in cells suggests that phosphorylated tau may hold toxic dangers for cell viability, and the response of the cell is to harness a variety of protective mechanisms. These include binding to chaperones, which may prevent more toxic conformations of the protein, ubiquitination which will direct the protein to the proteasome, segregation of tau aggregates from the cellular machinery, and recruitment of Hsp27 which will confer anti-apoptotic properties to the cell.
Elsevier